ArticlePlant biotechnology journal2025
Duckweed-based edible vaccine confers complete protection against avian infectious bronchitis virus by inducing robust mucosal and systemic immunity.
Article in Plant biotechnology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Novel insights intomSystems · 2026Article
- Review
- Chromosome-Scale Genome Assemblies of Duckweeds Provide Insights Into Genomic Plasticity, Aquatic Adaptation, and Morphological Reduction.Genome biology and evolution · 2026Article
- Duckweeds: from fundamental biology to a sustainable plant chassis for biotechnology.Advanced biotechnology · 2026Review
- From models to medicine: systematic development and evaluation of animal models forFrontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Molecular farming using edible plants offers a cost-effective strategy for vaccine production because plants serve as both bioreactors and oral delivery systems. Owing to its rapid clonal propagation and high protein content, duckweed represents a promising platform for this purpose. Here, we developed an edible duckweed-based vaccine targeting avian infectious bronchitis virus (IBV), a highly contagious respiratory pathogen in poultry, and directly compared its efficacy to that of a commercial live-attenuated H120 vaccine. Transgenic duckweed expressing the IBV antigen peptide EpiC was orally administered to chickens, followed by immunological assessment and viral challenge. Without an adjuvant, the EpiC duckweed vaccine elicited robust systemic IgG and mucosal sIgA responses, conferring 100% protection against lethal IBV challenge - which is comparable to or exceeds the efficacy of the H120 vaccine. Strikingly, co-administration with duckweed expressing IL-17B as an adjuvant synergistically enhanced immune responses, including elevated IBV-specific IgGs in serum (P < 0.001), increased IBV-specific sIgAs in the trachea and kidney (P < 0.05), and reduced tracheal viral loads (P < 0.05). Transcriptomic analysis revealed the upregulation of B-cell receptors and enrichment of the IgA production pathway, indicating that sIgA-mediated mucosal immunity is a key protective mechanism. Histopathological analysis confirmed protection against IBV-induced tissue damage, whereas a reduced viral load in critical organs demonstrated systemic efficacy. By outperforming a licenced vaccine in head-to-head comparisons, this work highlights the readiness of duckweed for real-world adoption, offering transformative potential for combating mucosa-associated infections in the poultry industry and beyond.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.